Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enzastaurin with radiotherapy followed by maintenance in newly diagnosed MGMT-unmethylated glioblastoma
2007-000281-21Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of enzastaurin in glioblastoma (GBM), sponsored by Eli Lilly and Company. Primary endpoint: Progression-free survival at 6 months. Started Aug 2007; status: completed.
02
Drugs
enzastaurin
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on 2007-000281-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000281-21.